Curis Shares Outstanding 2006-2021 | CRIS

Curis shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Curis Annual Shares Outstanding
(Millions of Shares)
2020 49
2019 33
2018 33
2017 30
2016 27
2015 25
2014 17
2013 16
2012 16
2011 15
2010 15
2009 13
2008 13
2007 11
2006 10
2005 10
Curis Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 92
2021-03-31 92
2020-12-31 49
2020-09-30 55
2020-06-30 40
2020-03-31 34
2019-12-31 33
2019-09-30 33
2019-06-30 33
2019-03-31 33
2018-12-31 33
2018-09-30 33
2018-06-30 33
2018-03-31 33
2017-12-31 30
2017-09-30 29
2017-06-30 29
2017-03-31 28
2016-12-31 27
2016-09-30 26
2016-06-30 26
2016-03-31 26
2015-12-31 25
2015-09-30 26
2015-06-30 26
2015-03-31 22
2014-12-31 17
2014-09-30 17
2014-06-30 17
2014-03-31 17
2013-12-31 16
2013-09-30 16
2013-06-30 16
2013-03-31 16
2012-12-31 16
2012-09-30 16
2012-06-30 16
2012-03-31 17
2011-12-31 15
2011-09-30 15
2011-06-30 15
2011-03-31 15
2010-12-31 15
2010-09-30 15
2010-06-30 15
2010-03-31 15
2009-12-31 13
2009-09-30 13
2009-06-30 13
2009-03-31 14
2008-12-31 13
2008-09-30 13
2008-06-30 13
2008-03-31 13
2007-12-31 11
2007-09-30 12
2007-06-30 10
2007-03-31 10
2006-12-31 10
2006-09-30 10
2006-06-30 10
2006-03-31 10
2005-12-31 10
2005-09-30 10
2005-06-30 10
2005-03-31 10
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.733B $0.011B
Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29